UNION and Innovent collaborate on next-gen PDE4 inhibitor for inflammatory dermatology conditions

UNION therapeutics and Innovent Biologics have entered into a strategic collaboration and license agreement for the development and commercialisation of orismilast in China.

As per the agreement, UNION grants Innovent an exclusive license to research, develop and commercialise orismilast in China – including participating in and recruiting Chinese patients for potential future global studies of orismilast.

UNION will receive an upfront payment of $20 million and is further entitled to receive up to $247 million in milestone payments as well as tiered royalties on sales of orismilast in China. UNION will retain global rights for orismilast outside of China.

“We are very pleased to enter a collaboration with UNION. We have been impressed with our partner’s capability to advance the global development of orismilast and we are excited to help bring orismilast to patients in China,” said Dr. Yongjun Liu, President of Innovent.

“This collaboration further strengthens our position in autoimmune by adding a mid-stage potential best-in-class therapy into our portfolio.

“Innovent is proud to be an ideal partner for worldwide biotech and pharmaceutical companies in terms of accelerating the development and commercialisation progress of novel assets to benefit a broader patient population.”

Kim Kjøller, CEO of UNION therapeutics, added: “This agreement provides independent validation of our belief in the best-in-class potential of orismilast and expands our global footprint in an underserved market with significant potential.

“Partnering with pharmaceutical companies is core to our strategy of maximising the value of our product candidates, and we are therefore excited to enter this collaboration with an internationally recognised partner.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news